$1.52
3.18% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
NL0012661870
Symbol
IFRX
Sector
Industry

InflaRx N.V. Stock price

$1.52
+0.08 5.56% 1M
-0.22 12.64% 6M
-0.11 6.75% YTD
-2.61 63.20% 1Y
-1.07 41.31% 3Y
-1.41 48.12% 5Y
-13.47 89.86% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.05 3.18%
ISIN
NL0012661870
Symbol
IFRX
Sector
Industry

Key metrics

Market capitalization $89.50m
Enterprise Value $10.20m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 92.73
P/S ratio (TTM) P/S ratio 813.64
P/B ratio (TTM) P/B ratio 1.02
Revenue (TTM) Revenue $110.00k
EBIT (operating result TTM) EBIT $-57.27m
Free Cash Flow (TTM) Free Cash Flow $-46.20m
Cash position $80.37m
EPS (TTM) EPS $-0.86
P/E forward negative
P/S forward 555.91
EV/Sales forward 63.36
Short interest 0.42%
Show more

Is InflaRx N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

InflaRx N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a InflaRx N.V. forecast:

4x Buy
80%
1x Hold
20%

Analyst Opinions

5 Analysts have issued a InflaRx N.V. forecast:

Buy
80%
Hold
20%

Financial data from InflaRx N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
0.11 0.11
-
100%
- Direct Costs 1.42 1.42
-
1,291%
-1.30 -1.30
-
-1,182%
- Selling and Administrative Expenses 20 20
-
18,091%
- Research and Development Expense 35 35
-
32,118%
-57 -57
-
-51,391%
- Depreciation and Amortization 0.74 0.74
-
673%
EBIT (Operating Income) EBIT -57 -57
-
-52,065%
Net Profit -51 -51
-
-46,018%

In millions USD.

Don't miss a Thing! We will send you all news about InflaRx N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

InflaRx N.V. Stock News

Neutral
GlobeNewsWire
5 days ago
JENA, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the presentation of preclinical data for the company's novel oral C5aR inhibitor, INF904, at the 2024 European Meeting on Complement in Human Diseases (EMCHD) being held in Lübeck, Germany, September...
Neutral
GlobeNewsWire
12 days ago
JENA, Germany, Aug. 27, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will participate in two investor conferences in September 2024. Details are as follows:
Neutral
GlobeNewsWire
about one month ago
JENA, Germany, Aug. 08, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced financial results for the three and six months ended June 30, 2024, and provided an operating update.
More InflaRx N.V. News

Company Profile

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products includes IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.

Head office Netherlands
CEO Niels Riedemann
Employees 66
Founded 2007
Website www.inflarx.de

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today